Andere talen Aldeyra Therapeutics, Inc.

Aandelen

ALDX

US01438T1060

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
4,16 ^USD	-1,19%		+5,85%	+18,52%

02/05	Aldeyra Therapeutics, Inc. rapporteert resultaten voor het eerste kwartaal dat eindigde op 31 maart 2024	CI
25/04	Transcript : Aldeyra Therapeutics, Inc. - Special Call

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Aldeyra Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	02/05
Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day	25/04
Aldeyra Therapeutics to Host Research and Development Day on April 25, 2024	19/04
Aldeyra Therapeutics to Host Research & Development Day on April 25, 2024	18/04
North American Morning Briefing : Focus Turns to -2-	04/04
Aldeyra Therapeutics Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease	28/03
Aldeyra Therapeutics, Inc. Announces Clinical Development Plan for Resubmission of New Drug Application for Reproxalap in Dry Eye Disease	28/03
Aldeyra Therapeutics Insider Sold Shares Worth $580,760, According to a Recent SEC Filing	13/03
Aldeyra Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Aldeyra Therapeutics to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06/02
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of Rasp Platform in Systemic and Retinal Inflammatory Diseases	04/01
Aldeyra Therapeutics Provides Clinical and Regulatory Update and Announces Advancement of RASP Platform in Systemic and Retinal Inflammatory Diseases	04/01
Aldeyra Therapeutics, Inc. and Abbvie to Enter into the Co-Development, Co-Commercialization and License Agreement	21/12
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	20/12
Aldeyra Therapeutics Shares Jump as Skin Drug Shows Significant Improvement in Clinical Trial	19/12
Aldeyra Therapeutics' skin disease drug succeeds in mid-stage study	19/12
Aldeyra Therapeutics' eczema drug succeeds in mid-stage study	19/12
Aldeyra Therapeutics Announces Statistically and Clinically Significant Improvement from Baseline in Phase 2 Clinical Trial of ADX‑629 in Patients with Atopic Dermatitis	19/12
Aldeyra Therapeutics, Inc. Announces Positive Top-Line Results from A Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	19/12
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Top-Line Results from Phase 2 Clinical Trial of ADX-629 in Patients with Atopic Dermatitis	18/12

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Aldeyra Therapeutics, Inc.

Aandelen

ALDX

US01438T1060

Andere talen

Filters